Wird geladen...

Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition

Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Proteome Res
Hauptverfasser: Sharma, Ritin, Fedorenko, Inna, Spence, Paige T., Sondak, Vernon K., Smalley, Keiran S.M., Koomen, John M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642956/
https://ncbi.nlm.nih.gov/pubmed/27934295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jproteome.6b00613
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!